J. Salvador

598 total citations
25 papers, 115 citations indexed

About

J. Salvador is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J. Salvador has authored 25 papers receiving a total of 115 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in J. Salvador's work include Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (10 papers) and Advanced Breast Cancer Therapies (5 papers). J. Salvador is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (10 papers) and Advanced Breast Cancer Therapies (5 papers). J. Salvador collaborates with scholars based in Spain, United States and Italy. J. Salvador's co-authors include Juan de la Haba-Rodríguez, Guillermo López-Vivanco, Álvaro Pascual, M. Carmen Conejo, Evelio J. Perea, Isabel Garcı́a, David Vicente, Monica G. Valero, M. Lomas and Reyes Bernabé and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

J. Salvador

23 papers receiving 113 citations

Peers

Countries citing papers authored by J. Salvador

Since Specialization

Citations

This map shows the geographic impact of J. Salvador's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Salvador with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Salvador more than expected).

Fields of papers citing papers by J. Salvador

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Salvador. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Salvador. The network helps show where J. Salvador may publish in the future.

Co-authorship network of co-authors of J. Salvador

This figure shows the co-authorship network connecting the top 25 collaborators of J. Salvador. A scholar is included among the top collaborators of J. Salvador based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Salvador. J. Salvador is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy 2024 ·npj Breast Cancer ·Sònia Pernas, Esther Sanfeliu, Guillermo Villacampa, J. Salvador, Antonia Perelló, Xavier González, Begoña Jiménez, Maria J. Merino, Patricia Palacios, Tomás Pascual, Emilio Alba, Lorea Villanueva, (unknown), (unknown), Patricia Galván, Aleix Prat, Eva Ciruelos	0
2	333P Ribociclib (RIB) + letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial 2020 ·Annals of Oncology ·Paul Cottu, Alistair Ring, Paolo Marchetti, Fátima Cardoso, J. Salvador, Patrick Neven, Konstantinos Papazisis, Mario Campone, Thomas Bachelot, (unknown), (unknown), (unknown), Michelino De Laurentiis	0
3	351TiP SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER) 2020 ·Annals of Oncology ·Mafalda Oliveira, Patricia Villagrasa, Eva Ciruelos, Joaquín Gavilá, (unknown), Fernando Henao, Estela Vega, J. Salvador, Vanesa Quiroga, (unknown), Serafín Morales, Pablo Tolosa, Fernando Salvador, Xavier González, Cristina Saura	1
4	Clinical impact of an educational antimicrobial stewardship program associated with infectious diseases consultation targeting patients with cancer: Results of a 9-year quasi-experimental study with an interrupted time-series analysis 2019 ·Journal of Infection ·José Molina, (unknown), José Antonio Lepe, María Antonia Pérez-Moreno, Manuela Aguilar‐Guisado, (unknown), Germán Peñalva, Juan Carlos Crespo‐Rivas, María Victoria Gil-Navarro, J. Salvador, José Miguel Cisneros	7
5	Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain 2017 ·Clinical & Translational Oncology ·Guillermo López-Vivanco, J. Salvador, (unknown), (unknown), (unknown), (unknown), Juan de la Haba-Rodríguez	41
6	Circulating LncRNAs as predictive biomarkers by molecular subtypes in advanced breast tumors. 2017 ·Journal of Clinical Oncology ·J. Salvador, (unknown), (unknown), (unknown), (unknown), Álvaro Montaño, (unknown), (unknown), (unknown)	1
7	Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions 2016 ·Clinical & Translational Oncology ·J. Salvador, (unknown), (unknown), Rosario García‐Campelo, (unknown), P. Lianes, Antonio Llombart‐Cussac, D. Casado, Jaume Piera, Montserrat Muñoz-Mateu, Javier Puente, (unknown), (unknown), Juan Antonio Virizuela, Miguel Martín, Pilar Garrido	10
8	Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer 2014 ·Clinical & Translational Oncology ·J. Salvador, Luís Manso, Juan de la Haba-Rodríguez, (unknown), Eva Ciruelos, (unknown), Mireia Gil-Raga, A Murias, António Galán de Mera, Carlos Jara, (unknown), José Manuel Baena, J. Casal, J. R. Mel, Isabel Blancas, (unknown)	10
9	Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital 2012 ·Clinical & Translational Oncology ·J. Salvador, (unknown), Joan Albanell, Agustín Barnadas, Pablo Borrega, Jesús García-Mata, Pilar Garrido, Encarnación González‐Flores, Dolores Isla, M. Lomas, Álvaro Rodríguez-Lescure, Juan Jesús Cruz, Emilio Alba	1
10	Functions and workload of medical oncologists in Spain 2012 ·Clinical & Translational Oncology ·(unknown), J. Salvador, Joan Albanell, Agustín Barnadas, Pablo Borrega, Jesús García-Mata, Pilar Garrido, Encarnación González‐Flores, Dolores Isla, M. Lomas, Álvaro Rodríguez-Lescure, Juan Jesús Cruz, Emilio Alba	6
11	Hyperglycemia after intratympanic dexamethasone treatment in a diabetic patient. 2011 ·PubMed ·(unknown), Francisco Javier Cervera‐Paz, J. Salvador, (unknown), Nicolás Pérez‐Fernández	2
12	Cisplatin, gencitabine, and lapatinib in patients with HER2-positive metastatic breast cancer: An experience in routine clinical practice. 2011 ·Journal of Clinical Oncology ·Monica G. Valero, Manuel Ruíz‐Borrego, J. Salvador, (unknown), María Luisa Limón, José Fuentes Pradera, Adriano de Paula Sabino, (unknown), L. Iglesias	2
13	Different Treatment Benefit for Luminal A and Luminal B Advanced Breast Cancinomas Receiving Aromatase Inhibitors. 2009 ·Cancer Research ·Manuel Ruíz‐Borrego, (unknown), J. Salvador, F. Carabantes, (unknown), (unknown), Joaquín Martínez‐López, Juan de la Haba-Rodríguez, (unknown), Eduardo Martínez de Dueñas, (unknown), (unknown), A Murias, Alfonso Tortorella, C. Guzmán, José Palacios	2
14	A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer 2008 ·Clinical & Translational Oncology ·(unknown), M. Lomas, J. Salvador, (unknown), (unknown), (unknown), (unknown), (unknown), Reyes Bernabé, (unknown)	1
15	Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer 2008 ·Cancer Chemotherapy and Pharmacology ·(unknown), J. Salvador, (unknown), M. Lomas, (unknown), Monica G. Valero, Reyes Bernabé, David Vicente, José Jiménez, (unknown)	14
16	Docetaxel followed by capecitabine as first-line chemotherapy in metastatic breast cancer patients: Preliminary results 2005 ·Journal of Clinical Oncology ·Reyes Bernabé, (unknown), J. Salvador, M. Lomas, (unknown), José Manuel Baena, David Vicente, (unknown)	1
17	A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer 2003 ·Cancer Chemotherapy and Pharmacology ·Juan José Reina, Jorge Aparicio, J. Salvador, (unknown), Antonio Rueda, (unknown), Carlos Puente, Pablo Borrega, (unknown)	1
18	306 Optimox study: Folfox7 compared to folfox4 in metastatic colorectal cancer (CRC). Results of a randomized study 2003 ·European Journal of Cancer Supplements ·Thierry André, Andrés Cervantes, Arié Figer, F. Maindrault-Gœbel, Élisabeth Carola, Pierre-Luc Etienne, (unknown), J. Salvador, (unknown), Armand de Gramont	1
19	Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils 1996 ·Journal of Antimicrobial Chemotherapy ·Isabel Garcı́a, Álvaro Pascual, J. Salvador, M. Carmen Conejo, Evelio J. Perea	8
20	Effect of antimicrobial and antineoplastic drugs on the uptake of fluconazole by human neutrophils and tissue culture cells 1993 ·European Journal of Clinical Microbiology & Infectious Diseases ·Isabel Garcı́a, Álvaro Pascual, (unknown), J. Salvador, Evelio J. Perea	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact